Mitiperstat（Cat No.:I045101）is an investigational myeloperoxidase (MPO) inhibitor developed to target oxidative stress and inflammation associated with cardiovascular and neurodegenerative diseases. By inhibiting MPO—a key enzyme in neutrophils that generates reactive oxygen species—Mitiperstat reduces tissue damage, vascular inflammation, and lipid oxidation. It is being explored for therapeutic potential in conditions such as heart failure, atherosclerosis, and neuroinflammatory disorders. Mitiperstat aims to preserve mitochondrial function and improve endothelial health. Supplied for research focused on oxidative stress, innate immune responses, and MPO-driven pathological processes in chronic inflammatory diseases.